BioNTech-话题@MedSci

#BioNTech#

44篇内容 | 2593人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2093014, encodeId=175e209301435, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>的<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>联合<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>治疗<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>临床效果下降，但对<a href='/topic/show?id=1417e308648' target=_blank style='color:#2F92EE;'>#睾丸癌#</a>效果亮眼, objectTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, objectType=article, longId=739304, objectId=992ee39304e3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220914/1663150338689_5295905.jpg, objectUrl=/article/show_article.do?id=992ee39304e3, replyNumber=0, likeNumber=144, createdTime=2022-10-11, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=992ee39304e3, moduleTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=992ee39304e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391204, encodeId=bcca139120401, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, objectType=article, longId=739304, objectId=992ee39304e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=992ee39304e3, replyNumber=0, likeNumber=110, createdTime=2022-09-16, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=992ee39304e3, moduleTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=992ee39304e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391203, encodeId=57cb13912030f, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle= Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌, objectType=article, longId=737316, objectId=0e77e37316b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e77e37316b6, replyNumber=0, likeNumber=82, createdTime=2022-08-31, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e77e37316b6, moduleTitle= Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e77e37316b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391202, encodeId=2535139120237, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请, objectType=article, longId=736670, objectId=313be36670fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313be36670fc, replyNumber=0, likeNumber=0, createdTime=2022-08-24, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313be36670fc, moduleTitle=辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313be36670fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391201, encodeId=bd0413912010b, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, objectType=article, longId=724120, objectId=4f46e241201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f46e241201a, replyNumber=0, likeNumber=91, createdTime=2022-04-14, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f46e241201a, moduleTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f46e241201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391200, encodeId=f35813912001b, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞/BioNTech旗下COVID-19疫苗Comirnaty：推迟决定是否让5岁以下幼童接种Comirnaty, objectType=article, longId=295529, objectId=9c5d2955294a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5d2955294a, replyNumber=0, likeNumber=114, createdTime=2022-02-14, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5d2955294a, moduleTitle=辉瑞/BioNTech旗下COVID-19疫苗Comirnaty：推迟决定是否让5岁以下幼童接种Comirnaty, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c5d2955294a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391199, encodeId=dda5139119900, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=梅斯早读丨CDC：感染奥密克戎病例约占全美新病例的99.9%；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, objectType=article, longId=294831, objectId=e368294831ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368294831ab, replyNumber=0, likeNumber=78, createdTime=2022-01-29, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368294831ab, moduleTitle=梅斯早读丨CDC：感染奥密克戎病例约占全美新病例的99.9%；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368294831ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391198, encodeId=77701391198f0, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=2022年1月26日简报：奥密克戎病例约占全美新病例的99.9%；奥密克戎亚型突变株BA.2的病例正在增加；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, objectType=article, longId=294735, objectId=a9db294e35e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9db294e35e9, replyNumber=0, likeNumber=85, createdTime=2022-01-27, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9db294e35e9, moduleTitle=2022年1月26日简报：奥密克戎病例约占全美新病例的99.9%；奥密克戎亚型突变株BA.2的病例正在增加；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9db294e35e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391197, encodeId=d83b139119e28, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=早期数据显示 Omicron 部分避开了辉瑞和 BioNTech COVID-19 疫苗, objectType=article, longId=221777, objectId=6a71221e773b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a71221e773b, replyNumber=0, likeNumber=85, createdTime=2021-12-11, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a71221e773b, moduleTitle=早期数据显示 Omicron 部分避开了辉瑞和 BioNTech COVID-19 疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a71221e773b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391196, encodeId=23cc139119624, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞和BioNTech的COVID-19疫苗Comirnaty对青少年具有高度保护作用, objectType=article, longId=218969, objectId=c1c72189695d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c72189695d, replyNumber=0, likeNumber=89, createdTime=2021-10-22, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c72189695d, moduleTitle=辉瑞和BioNTech的COVID-19疫苗Comirnaty对青少年具有高度保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c72189695d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391195, encodeId=ecf3139119530, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变, objectType=article, longId=218235, objectId=e8f2218235c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8f2218235c1, replyNumber=0, likeNumber=91, createdTime=2021-10-10, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8f2218235c1, moduleTitle=BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8f2218235c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391194, encodeId=e06a1391194b7, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=美国FDA全面批准辉瑞BioNTech新冠mRNA疫苗，美军将全员接种, objectType=article, longId=216255, objectId=a27c21625501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a27c21625501, replyNumber=0, likeNumber=79, createdTime=2021-08-26, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a27c21625501, moduleTitle=美国FDA全面批准辉瑞BioNTech新冠mRNA疫苗，美军将全员接种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a27c21625501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391193, encodeId=b2e4139119351, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTechQ2财报亮眼，4项临床试验针对Delta变种, objectType=article, longId=215544, objectId=3725215544f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3725215544f1, replyNumber=0, likeNumber=90, createdTime=2021-08-12, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3725215544f1, moduleTitle=BioNTechQ2财报亮眼，4项临床试验针对Delta变种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3725215544f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391192, encodeId=e71d13911921a, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTech 计划开发一种 mRNA 疫苗来预防疟疾, objectType=article, longId=215299, objectId=943c21529991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=943c21529991, replyNumber=0, likeNumber=111, createdTime=2021-08-06, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=943c21529991, moduleTitle=BioNTech 计划开发一种 mRNA 疫苗来预防疟疾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=943c21529991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391191, encodeId=98c813911915b, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=复星医药与BioNTech研发的新冠疫苗通过中国专家组审核, objectType=article, longId=214285, objectId=9f1121428517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1121428517, replyNumber=0, likeNumber=81, createdTime=2021-07-17, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1121428517, moduleTitle=复星医药与BioNTech研发的新冠疫苗通过中国专家组审核, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1121428517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391190, encodeId=07ff13911908c, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=美国FDA批准辉瑞/BioNTech新冠疫苗用于12-15岁青少年, objectType=article, longId=211125, objectId=10da2111256e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10da2111256e, replyNumber=0, likeNumber=100, createdTime=2021-05-13, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10da2111256e, moduleTitle=美国FDA批准辉瑞/BioNTech新冠疫苗用于12-15岁青少年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10da2111256e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391189, encodeId=821b1391189dd, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTech将在新加坡、中国设厂生产mRNA新冠疫苗, objectType=article, longId=211118, objectId=aa5d21111858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa5d21111858, replyNumber=0, likeNumber=84, createdTime=2021-05-13, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa5d21111858, moduleTitle=BioNTech将在新加坡、中国设厂生产mRNA新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa5d21111858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391188, encodeId=06e71391188ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化, objectType=article, longId=211060, objectId=0efc211060e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0efc211060e6, replyNumber=0, likeNumber=97, createdTime=2021-05-11, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0efc211060e6, moduleTitle=2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0efc211060e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391187, encodeId=f97a139118e28, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=复星医药/BioNTech在中国设立合资公司：mRNA新冠疫苗复必泰年产能达10亿剂，预计7月前被国内批准上市, objectType=article, longId=211050, objectId=500e2110502a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500e2110502a, replyNumber=0, likeNumber=100, createdTime=2021-05-11, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500e2110502a, moduleTitle=复星医药/BioNTech在中国设立合资公司：mRNA新冠疫苗复必泰年产能达10亿剂，预计7月前被国内批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500e2110502a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391186, encodeId=768213911864f, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=欧盟将2年内购买至少18亿剂辉瑞与BioNtech新冠疫苗, objectType=article, longId=211027, objectId=c67821102e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c67821102e60, replyNumber=0, likeNumber=81, createdTime=2021-05-11, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c67821102e60, moduleTitle=欧盟将2年内购买至少18亿剂辉瑞与BioNtech新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c67821102e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BioNTech

2020-05-29

lifestar (审核中...)

前往app查看评论内容

#BioNTech#的#mRNA疫苗#联合#CAR-T#治疗#实体瘤#临床效果下降，但对#睾丸癌#效果亮眼

BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼

2022-10-11

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼

2022-09-16

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌

2022-08-31

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞/BioNTech向FDA和EMA提交二价奥密克戎特异性mRNA疫苗上市申请

2022-08-24

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切

2022-04-14

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞/BioNTech旗下COVID-19疫苗Comirnaty：推迟决定是否让5岁以下幼童接种Comirnaty

2022-02-14

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

梅斯早读丨CDC：感染奥密克戎病例约占全美新病例的99.9%；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验

2022-01-29

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

2022年1月26日简报：奥密克戎病例约占全美新病例的99.9%；奥密克戎亚型突变株BA.2的病例正在增加；辉瑞和BioNTech就针对奥密克戎的新冠疫苗启动临床试验

2022-01-27

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

早期数据显示 Omicron 部分避开了辉瑞和 BioNTech COVID-19 疫苗

2021-12-11

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞和BioNTech的COVID-19疫苗Comirnaty对青少年具有高度保护作用

2021-10-22

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTech基于mRNA技术的癌症疫苗开启二期临床试验，新冠疫苗与药物市场格局恐生变

2021-10-10

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

美国FDA全面批准辉瑞BioNTech新冠mRNA疫苗，美军将全员接种

2021-08-26

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTechQ2财报亮眼，4项临床试验针对Delta变种

2021-08-12

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTech 计划开发一种 mRNA 疫苗来预防疟疾

2021-08-06

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

复星医药与BioNTech研发的新冠疫苗通过中国专家组审核

2021-07-17

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

美国FDA批准辉瑞/BioNTech新冠疫苗用于12-15岁青少年

2021-05-13

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTech将在新加坡、中国设厂生产mRNA新冠疫苗

2021-05-13

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化

2021-05-11

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

复星医药/BioNTech在中国设立合资公司：mRNA新冠疫苗复必泰年产能达10亿剂，预计7月前被国内批准上市

2021-05-11

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

欧盟将2年内购买至少18亿剂辉瑞与BioNtech新冠疫苗

2021-05-11

科室
- - 订阅+
  - 更多科室
工具
服务